Company Overview

Update
Founded:
2003
Headquarters:
San Rafael
IPO:
Went Public on Jul 23, 1999
Stock:
BMRN
Categories:
Pharmaceuticals
Description:
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.

Detailed Description

Update

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany.

Current Team (1)

Update

Past Team (6)

Update

Board Members and Advisors (1)

Update

Acquisitions (3)

Update

Offices/Locations (1)

Update
  • Headquarters

    770 Lindaro Street

    San Rafael, 94901

Images (1)

Update
  • R7poqm0woth5svypvy8s